Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia

被引:17
作者
Chen, Rong [1 ]
Plunkett, William [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
chronic lymphocytic leukaemia; therapy; transcription inhibitor; translation inhibitor; cyclin-dependent kinase; anti-apoptotic proteins; CYCLIN-DEPENDENT KINASE; SMALL-MOLECULE INHIBITOR; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; CHRONIC MYELOGENOUS LEUKEMIA; CYC202; R-ROSCOVITINE; RNA-POLYMERASE-II; MYC MESSENGER-RNA; B-CELL LYMPHOMA; IN-VITRO; DOWN-REGULATION;
D O I
10.1016/j.beha.2010.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukaemia (CLL) is characterised by the dependence on the overexpression of anti-apoptotic proteins to maintain their survival. Based on this biological context, a strategy for CLL therapy was proposed using inhibitors of transcription and translation to transiently reduce the short-lived survival proteins and induce cell death. This includes inhibitors of the cyclin-dependent kinases required for the activation of RNA polymerase II, as well as homoharringtonine and silvestrol, the natural compounds that inhibit translation. As their actions are independent of p53 or ataxia telangiectasia mutated (ATM) function, agents that act by such mechanisms are promising to overcome resistance to current CLL therapy. Further, the combination of inhibitors of transcription and translation, together with other approaches that interfere with the function of anti-apoptotic proteins, may initiate synergistic killing in CLL. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:155 / 166
页数:12
相关论文
共 101 条
[1]   A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival [J].
Alvi, AJ ;
Austen, B ;
Weston, VJ ;
Fegan, C ;
MacCallum, D ;
Gianella-Borradori, A ;
Lane, DP ;
Hubank, M ;
Powell, JE ;
Wei, WB ;
Taylor, AMR ;
Moss, PAH ;
Stankovic, T .
BLOOD, 2005, 105 (11) :4484-4491
[2]  
[Anonymous], J CLIN ONCOLOGY
[3]   Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion [J].
Austen, Belinda ;
Skowronska, Anna ;
Baker, Claire ;
Powell, Judith E. ;
Gardiner, Anne ;
Oscier, David ;
Majid, Aneela ;
Dyer, Martin ;
Siebert, Reiner ;
Taylor, A. Malcolm ;
Moss, Paul A. ;
Stankovic, Tatjana .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5448-5457
[4]   bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells [J].
Blagosklonny, MV ;
Alvarez, M ;
Fojo, A ;
Neckers, LM .
LEUKEMIA RESEARCH, 1996, 20 (02) :101-107
[5]   Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model [J].
Bordeleau, Marie-Eve ;
Robert, Francis ;
Gerard, Baudouin ;
Lindqvist, Lisa ;
Chen, Samuel M. H. ;
Wendel, Hans-Guido ;
Brem, Brigitte ;
Greger, Harald ;
Lowe, Scott W. ;
Porco, John A., Jr. ;
Pelletier, Jerry .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (07) :2651-2660
[6]   Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 [J].
Byrd, JC ;
Shinn, C ;
Waselenko, JK ;
Fuchs, EJ ;
Lehman, TA ;
Nguyen, PL ;
Flinn, IW ;
Diehl, LF ;
Sausville, E ;
Grever, MR .
BLOOD, 1998, 92 (10) :3804-3816
[7]   Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].
Byrd, John C. ;
Lin, Thomas S. ;
Dalton, James T. ;
Wu, Di ;
Phelps, Mitch A. ;
Fischer, Beth ;
Moran, Mollie ;
Blum, Kristie A. ;
Rovin, Brad ;
Brooker-McEldowney, Michelle ;
Broering, Sarah ;
Schaaf, Larry J. ;
Johnson, Amy J. ;
Lucas, David M. ;
Heerema, Nyla A. ;
Lozanski, Gerard ;
Young, Donn C. ;
Suarez, Jose-Ramon ;
Colevas, A. Dimitrios ;
Grever, Michael R. .
BLOOD, 2007, 109 (02) :399-404
[8]  
Carlson B, 1999, CANCER RES, V59, P4634
[9]   Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol [J].
Cencic, Regina ;
Carrier, Marilyn ;
Galicia-Vazquez, Gabriela ;
Bordeleau, Marie-Eve ;
Sukarieh, Rami ;
Bourdeau, Annie ;
Brem, Brigitte ;
Teodoro, Jose G. ;
Greger, Harald ;
Tremblay, Michel L. ;
Porco, John A., Jr. ;
Pelletier, Jerry .
PLOS ONE, 2009, 4 (04)
[10]   Flavopiridol inhibits P-TEFb and blocks HIV-1 replication [J].
Chao, SH ;
Fujinaga, K ;
Marion, JE ;
Taube, R ;
Sausville, EA ;
Senderowicz, AM ;
Peterlin, BM ;
Price, DH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (37) :28345-28348